Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Enrique Grande, José Ángel Arranz, Maria De Santis, Aristotelis Bamias, Eiji Kikuchi, Xavier García del Muro, Se Hoon Park, Ugo De Giorgi, B. Yа. Alekseev, Marina Mencinger, Kouji Izumi, Fabio A.B. Schutz, Javier Puente, Jian‐Ri Li, Peter H. O’Donnell, Arash Rezazadeh Kalebasty, Dingwei Ye, Sanjeev Mariathasan, FabioIa Bene-Tchaleu, Sandrine Bernhard, Chooi Lee, Ian D. Davis, Matthew D. Galsky
Topics & Concepts
Metastatic Urothelial CarcinomaAtezolizumabMedicineChemotherapyPlaceboOncologyInternal medicineUrothelial carcinomaCarcinomaUrologyCancerBladder cancerImmunotherapyPathologyPembrolizumabAlternative medicineBladder and Urothelial Cancer TreatmentsCholangiocarcinoma and Gallbladder Cancer StudiesIntraperitoneal and Appendiceal Malignancies